Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance
Philip J. Johnson(Prince of Wales Hospital), Takashi Kumada(Gifu Kyoritsu University), Paul B.S. Lai(Chinese University of Hong Kong), Mabel Teng(University of Cambridge), Hidenori Toyoda(Ogaki Municipal Hospital), Shinji Satomura(University of Cambridge), Chiaki Kagebayashi(University of Cambridge), Stephen L. Chan(Chinese University of Hong Kong), Toshifumi Tada(Himeji Red Cross Hospital), Sarah Berhane(University Hospitals Birmingham NHS Foundation Trust), Frankie Mo(Chinese University of Hong Kong), Richard Fox(Cancer Research UK Clinical Trials Unit), Winnie Yeo(Chinese University of Hong Kong)
Cited by 56
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection
|Cochrane Database of Systematic Reviews|2020|1.3k